Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

Friedeberg brings more than 16 years of experience in economic development, having previously held leadership roles with the ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (BMV:GMED) from Buy to Neutral. There are 759 funds or institutions reporting positions in Globus Medical.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Globus Medical, Inc. GMED reported first-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which missed the Zacks Consensus Estimate by 8.1%. The figure increased 7.9% year over year.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...